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Abstract
Context: Differentiated thyroid cancer (DTC) is usually treated by thyroidectomy followed 
by radioiodine ablation and generally has a good prognosis. It may now be possible to 
limit the amount of treatment without impacting on efficacy. It is not known whether 
coexistent thyroiditis impacts on radioiodine uptake or on its potential efficacy, but this 
could provide a rationale for modification to current therapeutic protocols.
Design: This was a retrospective cohort study of radioiodine uptake on imaging after 
radioiodine ablation for DTC in patients with and without concurrent thyroiditis. All 
patients with histologically confirmed DTC treated with radioiodine ablation after 
thyroidectomy in a single centre from 2012 to 2015 were included. The primary outcome 
assessed was the presence of low or no iodine uptake on post-ablation scan, as reported 
by a nuclear medicine physician blinded to the presence or absence of thyroiditis.
Results: One hundred thirty patients with available histopathology results were included. 
Thyroiditis was identified in 42 post-operative specimens and 15 of these patients had 
low or no iodine uptake on post-ablation scan, compared to only 2 of 88 patients without 
thyroiditis (P < 0.0001) with further data analysis dividing the groups by ablation activity 
received (1100 MBq or 3000 MBq).
Conclusions: Concurrent thyroiditis may impair the uptake of radioactive iodine in 
management of DTC. Given that patients with DTC and thyroiditis already have a good 
prognosis, adopting a more selective approach to this step in therapy may be indicated. 
Large, longitudinal studies would be required to determine if omitting radioactive iodine 
therapy from those patients with concurrent thyroiditis has a measurable impact on 
mortality from thyroid cancer.
Introduction
Differentiated thyroid cancer (DTC) is the most frequently 
occurring endocrine cancer and its incidence has been 
increasing steadily in men and women over the last few 
decades (1, 2, 3). DTC includes papillary thyroid cancer 
(PTC) and follicular thyroid cancer (FTC) and although 
the pathologies and natural history of these subtypes 
differ, the two share a common treatment pathway. 
Total thyroidectomy is recommended for nearly all 
patients with DTC, dependent on TNM staging, either as 
a single procedure if the DTC is proven by imaging and 
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fine-needle aspiration or as a diagnostic lobectomy 
followed by a completion thyroidectomy when the 
histology is confirmed.
Thyroidectomy is followed by replacement of thyroid 
hormone and in many cases, thyroid remnant ablation 
with 131I (4, 5, 6). Both total thyroidectomy and ablation 
contribute to optimal management by allowing the early 
detection of rising levels of thyroglobulin from a low post-
operative/ablation baseline. It is hoped that early detection 
of persistent or recurrent disease will improve disease-
free survival (7). Uptake of 131I into thyroid tissue is a 
prerequisite for remnant ablation. 131I is predominantly a 
beta emitter which provides the intracellular therapy, but 
concurrent gamma emission detected on post-ablation 
imaging demonstrates the extent and location of residual 
thyroid remnant or disease.
The exact activity of 131I required for thyroid remnant 
ablation has been controversial; for example, one study 
suggested that 1.1 GBq provided an ablation success rate 
20% lower than that provided by 3.7 GBq (8). Two large 
studies – ESTIMABL and HiLo – were devised to elucidate 
the effect of differing 131I activity and each concluded 
that 1.1 and 3.7 GBq were equivalent in terms of ablation 
success rate (6, 9). These studies have led to a change in 
UK practice over time because they have demonstrated 
how to minimise radiation exposure and the risk of 
potential side effects or complications (dry mouth, loss 
of taste sensation, reduced spermatogenesis and risk of 
secondary malignancies), while maximising the likelihood 
of successful remnant ablation. Further to this, the IoN 
trial is in progress to assess whether omitting radioiodine 
ablation altogether alters outcomes in low-risk DTC (10).
In keeping with this trend to minimise therapeutic 
intervention (radiation in particular) without 
compromising disease-free survival, we have sought to 
determine whether thyroiditis in patients with DTC 
is a factor which impacts on the therapeutic benefit of 
radioactive ablation and which can be used to stratify 
patients that may or may not benefit from RAI.
Patients with chronic lymphocytic thyroiditis have 
been shown to have an increased risk of PTC, and the 
coexistence of the two conditions has been reported in 
many studies over more than 20 years (11, 12). Although 
controversial, PTC in association with thyroiditis may 
have a better outcome and lower rates of recurrence (13, 
14, 15), but the cause is not clear. We hypothesise that 
thyroiditis may have an impact on the ability of DTC 
to take up 131I and in turn alter the success of attempted 
remnant ablation. In this study, we analyse the effect of the 
presence or absence of thyroiditis and different activities 
of 131I administered to a population with DTC over a 
period of years, spanning a change in standard clinical 
practice from a time when 3.7 GBq was administered 
to current practice of administering 1.1 GBq. We use 
radioiodine uptake as a surrogate marker for remnant 
ablation, because, while uptake may not be synonymous 
with ablation it can be assumed to be a prerequisite.
Materials and methods
Study population
This was a retrospective study of patients with DTC who 
underwent total thyroidectomy from January 2012 to 
December 2015 at St. Bartholomew’s Hospital, Barts Health 
NHS Trust, UK. Permission for this quality improvement 
project was obtained from the institutional quality 
improvement review board (project number 7352). As 
retrospective audit of current standard of clinical practice, 
consent was not required from the patients.
Treatment protocol
All patients underwent routine preoperative thyroid 
function tests, ultrasonography of neck and fine-needle 
aspiration cytology (FNAC) of the primary tumour and 
were confirmed to have DTC pathologically after thyroid 
surgery (hemi-thyroidectomy or total thyroidectomy).
The standard ‘traditional’ 131I activity administered 
for remnant ablation at the start of the study period 
was 3000 MBq (80 mCi). This was subsequently lowered 
to 1100 MBq (30 mCi) especially for low-risk patients, 
based on data from the ESTIMABL and HiLo studies 
(6, 9). The cohort described contains individuals who 
received either ‘traditional’ or low-dose ablation. Prior 
to therapy, patients were advised to eat a diet low in 
iodine for 1–2  weeks and all doses were administered 
under conditions of high TSH, predominantly achieved 
with recombinant TSH. Patients were quarantined upon 
administration of 131I with specific advice for radiation 
protection. Patients were discharged when the radiation 
exposure measured was <30 microsievert/h, at a distance 
of one metre from the patient. Thyroid function tests and 
serum thyroglobulin were measured at regular intervals 
after RAI for surveillance with a further 123I scan if the 
post-ablation scan showed uptake in the thyroid bed only. 
The timing of this initial follow-up scan was at 6 months 
up until mid-2014, after which it occurred at 9 months, 
due to a change in our institution’s standard practice. 
Patients were scheduled for 131I therapy if there were 
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iodine-avid metastases on the end-of-post-ablation scan 
performed during admission for ablation.
Data collection
Patient data were collected and recorded by 
retrospective review of patient records, searching first 
for all patients with DTC treated with remnant ablation 
following thyroidectomy and included for further 
analysis if histopathology from thyroidectomy was 
available. Standard patient data collected included 
patient demographics (age and gender), preoperative 
investigation findings (thyroid function tests analysed 
by immunoradiometric assay and ultrasound scan of 
the thyroid gland) and preoperative cytology, as well as 
serum thyroglobulin levels from the time of the first post-
ablation scan onwards. Tests for anti-thyroid antibodies, 
when performed, used immunometric assays ECLIA and 
ELISA. Only the parameters contributing to the subject of 
our quality review are reported here.
Data on the presence of thyroiditis were collected 
from evaluation of histopathology reports. All thyroid 
specimens after thyroidectomy were examined by an 
endocrine pathologist (the same specialist across more 
than 70% of cases) and were commented on for gross 
appearance, microscopic features of the tumour and an 
assessment of any background inflammatory infiltrate 
in the non-neoplastic thyroid. Thyroiditis was defined 
as significant numbers of lymphocytes infiltrating the 
normal thyroid parenchyma away from the neoplastic 
process. Where possible, thyroiditis was graded as mild, 
moderate or severe, based on the intensity of the infiltrate 
and presence of secondary lymphoid follicles although 
due to the subjective nature of this grading, it was not 
included in subsequent data analysis.
Data from post-ablation uptake were obtained via 
the imaging reports provided by the nuclear medicine 
department. Intensity of uptake was judged as absent, low 
or intense by a nuclear medicine physician unaware of the 
results of the pathology report at the time of reporting.
Statistical analysis
All statistical analyses were performed using SPSS, version 
23 and Microsoft Office Excel 2016. Demographic data 
were analysed using descriptive statistics. A chi-square 
(χ2) test determined whether distributions of categorical 
variables differed from one another. Initial data were 
divided into two groups: ‘DTC with thyroiditis’ and 
‘DTC without thyroiditis’ and compared across various 
parameters including 131I uptake. Data were further 
analysed based on the 131I activity administered (1100 or 
3000 MBq). Continuous variables have been expressed as 
mean ± s.d. and categorical variables have been expressed 
as numbers and percentages. Continuous variables 
were compared by t-test where normally distributed. 
Categorical variables – the association between thyroiditis 
and gender and between thyroiditis and low RAI uptake – 
were assessed using the two-tailed Fisher’s exact test. The 
statistical level of significance was considered as P < 0.05.
Results
Patients with DTC treated with thyroidectomy and 131I 
ablation from 2012 to 2015 inclusive numbered 187, 
consisting of 132 females and 55 males, with mean age 
47 ± 12 years. Histopathology reports could not be traced 
for 57 patients whose thyroidectomy was undertaken in 
other hospitals and had been referred to our institution 
for radioiodine therapy and surveillance. Our standard 
practice is to review the pathology blocks of such 
patients in our own department where possible but, 
having confirmed the primary diagnosis of DTC, blocks 
are returned to the referring hospital and may not have 
remained onsite for subsequent audit-based analysis such 
as that reported here. Of the 130 patients with complete 
data available, 91 (70%) were females and 39 (30%) were 
males; this suggests that the analysed cohort was reflective 
of the wider DTC population. PTC with or without 
metastasis was the most common diagnosis, followed by 
FTC and Hurthle cell carcinoma. Of the analysed cohort, 
96 patients (73.8%) received 1100 MBq and 34 patients 
(26.1%) received an ablation activity of 3000 MBq (Fig. 1 
and Table 1).
Of the 130 DTC patients with available histopathology, 
42 (32%) had demonstrable thyroiditis on histopathology. 
Females accounted for 33 of these cases. The mean age 
for patients with thyroiditis was 43 ± 14  years. There 
were 88 patients without coexisting thyroiditis (67%) of 
whom 58 were female. There were more female patients 
in the cohort overall but no statistically significant 
difference between the male and female preponderance 
of thyroiditis. The mean age for the group of patients 
without thyroiditis was 49.0 ± 16  years. There was no 
statistically significant difference in age between the two 
groups (P = 0.053) (Table 1).
For the 42 patients with thyroiditis, 9 were 
documented as having abnormal thyroid function 
prior to thyroidectomy (6 hypothyroid or compensated 
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hypothyroid and 3 with suppressed TSH or frankly 
hyperthyroid), while for the 88 patients without 
thyroiditis, 5 were documented as having abnormal 
thyroid function (1 hypothyroid). There was inconsistent 
practice in measuring thyroid antibody status 
preoperatively, particularly in patients with normal 
preoperative thyroid function, so statistical analysis has 
not been performed for this parameter.
On more detailed review of pathology reports, extra-
thyroidal extension of DTC was seen significantly less 
frequently in patients with thyroiditis: 8 patients compared 
to 29 patients in the group without thyroiditis (P = 0.028). 
Patients with thyroiditis were also found to have a lower 
likelihood of concurrent lymph node metastasis at the 
time of surgery – 16 patients compared to 31 without 
thyroiditis – although this finding was not statistically 
significant (P = 0.7). Additional adverse histological 
features were not especially apparent in patients with low 
or no uptake; only one patient with low uptake was noted 
to have poorly differentiated features, albeit still within 
the pathological definition of follicular thyroid carcinoma.
Thyroiditis was identified in 42 post-operative 
specimens and 15 of these patients had low or no iodine 
uptake on post-ablation scan, compared to only 2 of 
88 patients without thyroiditis (P < 0.0001). To exclude 
the possibility that 131I activity administered was a 
confounding factor in the uptake of radioactive iodine, in 
order to examine the effects of the presence of thyroiditis 
on radioiodine uptake, patients were divided for analysis 
into two groups: 1100 MBq administered or 3000 MBq 
administered. The variables of ‘with thyroiditis’ and 
‘without thyroiditis’, and the degree of uptake (‘moderate 
or intense’ and ‘low or no’) were compared within the 
groups and between the groups. DTC patients who received 
1100 MBq numbered 96 in total. Among these, 30 had 
coexisting thyroiditis. Of the 30 patients with thyroiditis, 
12 had low or no radioiodine uptake (three had no uptake 
and nine had low uptake). These data were compared to 
the uptake in those patients without thyroiditis who also 
received 1100 MBq. Of the 66 patients without thyroiditis, 
only one had low (or no) radioiodine uptake. Patients 
with thyroiditis showed higher prevalence of low or no 
Figure 1
Patient flow chart. Patients with differentiated 
thyroid carcinoma (DTC) by number, sex (F, 
female or M, male), presence or absence of 
thyroiditis and radioactive iodine activity 
administered (1100 or 3000 MBq).
Table 1 Demographics of cohort.
Number
Sex Age (years) Abnormal thyroid status prior  
to thyroidectomyFemale Male Mean Median
All patients with DTC and ablation therapy 187 132 55 48 47 26
Total included (histopathology available) 130 91 39 47 46 14
With thyroiditis 42 33 9 43 44 9
Without thyroiditis 88 58 30 49 50 5
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radioiodine uptake compared to the patients without 
thyroiditis (P < 0.001) (Table 2).
A total of 34 patients received 3000 MBq of 131I for 
ablation, 12 patients had thyroiditis and 22 did not have 
thyroiditis. Out of the 12 patients with thyroiditis 3 
(25.0%) showed low or no uptake. Out of the 22 patients 
who were without thyroiditis, one (0.05%) had low or no 
uptake (P = 0.08) (Table 2).
The relationship between administering 1100 MBq 
or 3000 MBq and a post-ablation scan recording intense 
radioactive iodine uptake was not significant in the total 
cohort (P = 0.79) or within the group with thyroiditis 
(P = 0.18) (Table 3).
Thyroglobulin was measured as a tumour marker 
following ablation in 41 of 42 patients with thyroiditis 
and was found to be suppressed to an undetectable level 
in 27 patients. Post-ablation scans demonstrated low 
or no uptake in 15 of the 42 patients with thyroiditis. 
The majority had a suppressed thyroglobulin and three 
patients had detectable thyroglobulin at 6 months. A 9- to 
12-month follow-up I-123 scan was performed in 32 of the 
42 thyroiditis patients and 29 of these scans demonstrated 
minimal or no uptake. There was concordant reduction in 
post-ablation thyroglobulin in all but 2 patients, with 17 
patients achieving complete suppression of thyroglobulin.
Post-surgical but pre-ablation thyroglobulin is 
likewise not measured as standard practice but results are 
available for 20 of these patients, which limits possible 
comparison of pre- and post-ablation thyroglobulin as 
part of retrospective analysis of the utility of radioiodine 
administration. Thyroglobulin was low prior to ablation 
in 10 patients and remained so subsequently in all 10; 
out of the other 10, 3 patients achieved total suppression 
after ablation and 3 patients had a documented 
reduction in thyroglobulin, without complete suppression. 
A rise in thyroglobulin despite apparent ablation was 
identified in four patients.
Discussion
DTCs originate from thyroid follicular cells. The majority 
are classified as PTC with a minority of FTC. PTC is 
the most common thyroid cancer and it carries a good 
prognosis with a 10-year disease-free survival rate of 93%. 
Consistent with other studies, our study demonstrated 
a positive relationship between thyroiditis and certain 
positive predictors of outcome in patients with DTC. The 
group of patients ‘with thyroiditis’ had a lower rate of 
extra-thyroidal extension and a non-significant reduction 
in lymph node metastasis (12, 13, 14). It is therefore 
possible that coexisting thyroiditis with DTC may be one 
of the determinants of reduced morbidity and mortality 
in patients with DTC. Our specific objective was to assess 
the immediate impact of thyroiditis on radioiodine 
uptake, rather than the success of long-term ablation, 
which is beyond the scope of this paper. Therefore, we did 
not review the degree of extra-thyroidal uptake seen on 
the post-ablation or direct detailed analysis towards the 
available thyroglobulin data, which was used as part of 
surveillance monitoring from the post-surveillance scan 
onwards.
While thyroiditis has not been demonstrated in 
studies to be an independent determinant of prognosis, 
the finding that outcomes tend to be better in this group 
means that it is important to consider the potential 
impact of thyroiditis as well as its potential utility in 
strategic planning of management. If the remnant is being 
destroyed by the autoimmune phenomenon, then the 
cancer should still be vulnerable to destruction by such 
Table 2 Presence of thyroiditis and of no/low uptake on imaging after 131I ablation.
 
Ablation activity (MBq)
Total number of 
patients
Number of patients 
with low/no uptake P value
With thyroiditis (n = 42) 1100 30 12 0.000002 for patients receiving 
1100 MBq3000 12 3
Without thyroiditis (n = 88) 1100 66 1 0.08 for patients receiving 
3000 MBq3000 22 1
Table 3 The different activity of RAI administered was not a significant direct factor in yielding no or low uptake in the cohort as 
a whole or in the group with thyroiditis.
1100 MBq 3000 MBq P value
All patients No/low uptake 13 4 0.792
(n = 130) Intense uptake 83 30
With thyroiditis No/low uptake 12 3 0.18
(n = 42) Intense uptake 18 9
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inflammation even in the absence of 131I administration. 
Thereafter, research could examine the impact of 
thyroiditis and omission of RAI on long-term prognosis.
One of the postulated mechanisms by which thyroiditis 
may improve prognosis has been through the presence of 
thyroid autoantibodies. These antibodies, through their 
autoimmune response to thyroid-specific antigens, may 
cause destruction of cancer cells which further reduces the 
chances of metastasis or recurrence (1, 16, 17). Separate 
reports have suggested that DTC, especially PTC with 
autoimmune thyroiditis, exhibit cytotoxic T-cell-mediated 
reactions (12, 18). Therefore, Hashimoto’s thyroiditis may 
facilitate destruction of cancer cells and prevent further 
tumour growth via both humoral and cytotoxic immune 
responses. Thyroid antibody production promotes 
progression to hypothyroidism because higher levels 
of antibodies against thyroglobulin (Tg) and thyroid 
peroxidase (TPO) accompany deterioration of thyroid 
function. Thyroid autoantibody levels differ between 
goitrous and atrophic thyroiditis, and although high 
anti-thyroid antibody titres may provide an indication 
of the likelihood of overt hypothyroidism, no correlation 
between antibody titre and risk for hypothyroidism has 
been identified (19, 20). Thyroid autoantibody testing 
can be useful for diagnosing or monitoring treatment; 
however, these tests should be employed selectively as 
adjunctive tests to other diagnostic testing procedures 
(20). There are limitations with the result of long-term 
monitoring: titres may remain positive for years and do 
not always predict abnormalities of thyroid function tests; 
some patients with well-defined Hashimoto's disease may 
have undetected antibodies, and conversely, patients 
with positive TPO antibodies may never develop thyroid 
disease (20).
Antibody reactions in autoimmune thyroiditis targeted 
towards thyroid-specific antigens may hasten thyroid 
destruction (21). It has also been postulated that PTC cells 
originating from follicular cells may express the antigens 
that the normal follicular cells produce (21). Accelerating 
the damage to a thyroid gland infiltrated with cancer cells, 
thyroiditis reduces morbidity and mortality and improves 
survival. Various studies have reported ≥ 95% disease-free 
10-year survival (11, 21). In our cohort, around 75% of 
the patients with thyroiditis had positive autoantibodies 
compared to 45.8% in the patients without thyroiditis; 
however, uncertainties about the antibody status of a 
number of patients in whom this was not recorded mean 
limited conclusions should be drawn.
The frequency of DTC with coexisting thyroiditis 
varies with age, gender and pre-existing autoimmune 
thyroid conditions. The variability has been reported to 
range from 0.5–30% (1).
The ability of DTC to retain the potential to trap 
iodine is an important avenue to exploit with radioiodine-
based diagnostics and therapeutics; the presence of 
abnormal thyroid function – and indeed the presence 
of histological thyroiditis – may impact on the retained 
potential for iodine trapping. In our study, patients with 
thyroiditis were significantly more likely to have low or 
no radioiodine uptake demonstrated on the post-ablation 
scan, with this seen more frequently after 1100 MBq 131I 
compared to 3000 MBq 131I. Patients with no uptake or 
less-intense uptake on the post-ablation scan could very 
well be true-negative cases following surgery; however, 
another possible explanation is that the presence of 
thyroiditis impacts radioiodine uptake. Therefore, without 
further longitudinal studies of outcomes in this type of 
patient, it is not possible to conclude with certainty that 
low uptake in these patients portends therapeutic benefit. 
The presence of thyroiditis may inhibit uptake to an 
extent that the activity administered is not sufficient to 
be visualised at all on the post-ablation scan, and it is also 
possible that there is little benefit to the patient while still 
being exposed to radiation.
It is important to note that thyroiditis is not the only 
potential reason for limited or poor radioiodine uptake. 
A negative whole-body scan in the presence of known 
residual or metastatic DTC is described (22). There are 
a number of well-described causes of false-negative 131I 
scans including inadequate TSH elevation, and iodine 
contamination from previous diagnostic use. We are 
confident that the patients in our study did not have 
negative scans for these reasons. There are also a number 
of potential reasons for true negative 131I scans that may 
relate to thyroid cancer but may also be over-represented 
in patients with thyroiditis. Any defect in the iodine-
trapping mechanism can lead to a change in the amount 
of radioiodine taken up by the DTC and a change of 
kinetics of iodine release from those cells, contributing 
to the negative scans (23). TPO is the key enzyme in 
the synthesis of thyroid hormones and is involved in 
two important reactions in the biosynthesis of thyroid 
hormone: the iodination of tyrosine residues on Tg and the 
intra-molecular coupling reaction of iodinated tyrosine. 
Thus, a balance between the sodium-iodide symporter 
(NIS)-mediated iodine influx and TPO-inhibited efflux 
determines the intracellular concentration of iodine in 
thyroid tissue. Any defect in symporter or TPO can cause 
a loss of iodine-trapping capacity. The loss of radioiodine 
uptake ability observed in some patients with DTC may 
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be ascribed to the reduced expression of an acquired 
mutation of the NIS or TPO genes (23).
The question remains whether the impact of 
thyroiditis on radioiodine uptake is sufficient to lead 
to change in clinical practice, particularly in this era of 
low-dose ablation in which the impact of thyroiditis 
on radioiodine uptake appears significant. It would be 
helpful to have predictors of low/no radioiodine uptake 
in addition to the presence of thyroiditis to refine the 
therapeutic pathway for these patients; however, further 
evaluation of this would require a larger cohort. There 
may be a case to be made for pre-testing patients with 
thyroiditis for radioiodine avidity (perhaps with a 123I 
scan) prior to considering RAI. The rationale for this relates 
to minimisation of radiation exposure to the patient as 
well as the potential minimisation of financial cost. An 
argument for pre-scanning based on cost-saving alone has 
insufficient strength at present based on a model using 
the data presented. This modelling assumes a standard 
of current practice in which all patients with positive 
histology undergo ablation with 1100 MBq 131I at a total 
cost per procedure of approximately £2000, accounting 
for the cost of thyrogen, nursing time for administration, 
radionuclide and hospital accommodation. Using 
our data, 32% of patients with histology positive for 
thyroiditis would first undergo 123I scanning at a cost of 
approximately £1100 per scan to assess whether sufficient 
uptake is seen to warrant ablation. Of these patients, our 
data suggest that fewer than 30% of this group would 
have no or low uptake on that scan, thus only ‘saving’ 
the ablation costs in 9% of the total patient cohort, which 
would not provide sufficient financial offset. However, 
this model does not take into account the key important 
saving of unwarranted radiation exposure to patients.
Conclusion
Our study has demonstrated that concurrent thyroiditis 
may impair uptake of radioactive iodine in management 
of DTC, particularly in this era of low-dose ablation. This 
urges consideration of whether this histological feature 
can be used to stratify patients in whom RAI is most 
likely to be of clinical utility. Further studies are required 
to assess prospectively the relevance of the severity and 
character of thyroiditis – focal, multifocal or diffuse – and 
any underlying molecular cause which might account 
for changes in 131I uptake and the success of remnant 
ablation. The end goal of determining whether thyroiditis 
influences morbidity and cancer-associated mortality will 
require a larger number of patients. Because DTC is overall 
a good-prognosis cancer and if, as the literature suggests, 
the patients with thyroiditis have a better prognosis 
still, then the impact of differential iodine uptake on 
the success of remnant ablation may result in an impact 
whose measurement would require a substantial 
longitudinal study.
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